Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 8, 2014 in Prostate cancer | 0 comments

In a nutshell

This study examined the link between androgen-deprivation therapy (ADT) and risk for developing heart attack or stroke in patients with prostate cancer.

Some background

Prostate cancer cells often require androgen hormones (male sex hormones such as testosterone) to grow. ADT is intended to reduce the production of androgens or inhibit their effect on cancer cell growth. ADT can involve either drug treatment with medical endocrine hormonal therapy or surgical removal of the testicles (orchiectomy). Drug treatment involves either the administration of gonadotropin-releasing hormone agonists (GnRH agonists; drugs that lower the production of testosterone in the body) or antiandrogens (block the action of androgens). The use of ADT has been indicated for the treatment of symptomatic, locally advanced (cancer has spread through the wall of the prostate) and metastatic prostate cancer (cancer that has spread to other organs).

Previous scientific studies suggest that there is an increased risk for heart attack and stroke in patients receiving ADT. However, this suggestion remains controversial. This study investigates if the increased risk exists.

Methods & findings

31,571 men with a primary diagnosis of prostate cancer and an average age of 71 were included. Patients were divided into three treatment groups: medical endocrine therapy (29%), orchiectomy (7%) and those receiving neither (64%). Patients were followed for an average of 3.3 years after diagnosis.

Compared to those not receiving ADT, those receiving medical endocrine therapy had a 31% increased risk of heart attack and a 19% increased risk of stroke.  This result held true even after statistically adjusting for patients’ age, cancer stage, study year, and all other co-existing medical conditions. An increased risk for heart attack and stroke was not seen in patients who underwent orchiectomy.

The bottom line

The authors concluded that medical endocrine therapy increased the risk for heart attack and stroke in patients with prostate cancer.

The fine print

As patients were not divided based on the specific endocrine therapy they received (GnRH agonists or antiandrogens) it is not clear whether one of these treatments is a bigger risk.

What’s next?

If considering ADT therapy, discuss the benefits and drawbacks of this treatment regimen with your doctor. If undertaking ADT, discuss the possibility of monitoring cardiovascular function with your doctor.

Published By :

European Urology

Date :

Mar 18, 2014

Original Title :

Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study.

click here to get personalized updates